Navigation Links
Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
Date:10/1/2013

CAMBRIDGE, Mass., Oct. 1, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of molecular prognostic and diagnostic tests for cancer, today announced that Cornelius J. Merlini, former general manager of HealthTronics Laboratory Solutions (HLS), has been appointed Metamark's Senior Vice President and Chief Commercial Officer.  In August 2013, Metamark acquired HLS, a national uropathology laboratory, from Endo Health Solutions, Inc.  Mr. Merlini will report to Metamark President and Chief Executive Officer, Shawn M. Marcell, and will join the company's senior leadership team.

"We are pleased that Cornelius has joined Metamark.  His exceptional leadership, commercial acumen, and track record bringing paradigm-changing products to market have produced transformational business growth," said Mr. Marcell.  "Cornelius already is an established leader of Metamark's newly-acquired uropathology business, where he assembled a talented, dedicated team – including a specialized national field sales force.  This commercial team nicely complements Metamark's innovative research and development efforts, and will accelerate the launch of ProMark™, our novel prostate cancer prognostic test."

"Metamark's strong science engine fits perfectly with its new commercial and operational machine," said Mr. Merlini.  "ProMark™ could redefine the management of early stage prostate cancer and become a standard test sought by patients and ordered by urologists when making well-informed treatment decisions.  It is exciting to join a company that could change the way prostate cancer is treated." 

Mr. Merlini has over twenty-five years of life science experience across a wide array of functions and businesses.  Prior to HealthTronics Lab Solutions, Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market leader in cord blood stem cell banking.  He spent ten years with increasing marketing, management and franchise leadership responsibilities at Johnson & Johnson, where he served most recently as Worldwide Vice-President of the cardiovascular franchise for Johnson & Johnson's biopharmaceutical business.  Earlier, Mr. Merlini gained successful sales and sales leadership experience with Marion Laboratories (now Sanofi-Aventis). 

About Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care.  The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers.  In early 2014, Metamark plans to commercialize ProMark™ – its prostate cancer prognostic test – through its Cambridge, Massachusetts CLIA-certified laboratory.  For more information, please visit the company's Website at www.metamarkgenetics.com.  Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
2. ACTUS Appoints New Members to Its Management Team
3. Immune Design Appoints Stephen R. Brady Chief Business Officer
4. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
5. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
6. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
7. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
8. Senn Chemicals Appoints New Chief Executive Officer
9. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
10. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
11. Alexander Proudfoot Appoints Executive Vice President for Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October ... on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker ... is free and open to the public, but registration is required. , WHAT: ...
(Date:10/5/2017)... ... 2017 , ... Understanding the microbiome, the millions of bacteria that live in ... Are My Future, the newest exhibit on display at the University City Science Center’s ... through the lens of the gut microbiome. , Gut Love opens October 12, ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):